You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Fallypride


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Fallypride?

Fallypride is an investigational drug.

There have been 18 clinical trials for Fallypride. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2009.

The most common disease conditions in clinical trials are Schizophrenia, Obesity, and Alcoholism. The leading clinical trial sponsors are Vanderbilt University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and Emory University.

Recent Clinical Trials for Fallypride
TitleSponsorPhase
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3National Institute on Drug Abuse (NIDA)Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3Emory UniversityPhase 3
Dopaminergic Dysfunction in Late-Life DepressionColumbia UniversityPhase 2

See all Fallypride clinical trials

Clinical Trial Summary for Fallypride

Top disease conditions for Fallypride
trials011223344556SchizophreniaObesityAlcoholismAlzheimer Disease[disabled in preview]
Top clinical trial sponsors for Fallypride
trials011223344556Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Emory University[disabled in preview]

See all Fallypride clinical trials

Fallypride: Development Update and Market Projections

Introduction

Fallypride, a small molecule under investigation, is being explored for its potential in various neurological and psychiatric applications. Here, we will delve into the current development status and potential market projections for this drug candidate.

Current Development Status

Fallypride is currently in the clinical trial phase, specifically in the investigation of its effects on striatal and extra-striatal dopamine release in response to food in healthy humans. The clinical trial, identified as NCT02310360, aims to understand the drug's mechanism of action and its impact on dopamine receptors[4].

Mechanism of Action

Fallypride is known as a high-affinity radioligand, often used in PET (Positron Emission Tomography) investigations to quantify striatal and extra-striatal D2/3 receptors. This makes it a valuable tool in studying dopamine receptor activity and its implications in neurological disorders[5].

Clinical Trials and Research

The ongoing clinical trial focuses on the striatal and extra-striatal dopamine release, which is crucial for understanding the drug's potential in treating conditions related to dopamine dysregulation, such as schizophrenia, Parkinson's disease, and other neuropsychiatric disorders. However, as of the latest available data, there is no indication of Fallypride being close to FDA approval or market launch in 2025[4].

Market Projections

Given the current stage of development, Fallypride is not expected to contribute significantly to the pharmaceutical market in the immediate future. However, its potential in the long term is promising, especially if it proves effective in treating conditions with high unmet medical needs.

Global Pharmaceutical Market Trends

The global pharmaceutical market is projected to grow significantly, with total prescription drug sales expected to reach $1.7 trillion by 2030, driven by innovations in "big drugs for big diseases" such as obesity and oncology[3].

Competitive Landscape

While Fallypride is not yet a player in the market, the landscape for neurological and psychiatric treatments is evolving rapidly. New modalities and technologies, including antibody-drug conjugates, cell/gene therapies, and radiopharmaceuticals, are gaining traction. If Fallypride can demonstrate clinical differentiation and efficacy, it could carve out a niche in this competitive space[3].

Challenges and Opportunities

Regulatory and Commercial Challenges

For Fallypride to become a marketable drug, it must navigate the regulatory approval process successfully. This involves demonstrating safety, efficacy, and a favorable risk-benefit profile. Additionally, commercialization strategies will be crucial to ensure patient access and market penetration[1].

Market Potential

If approved, Fallypride could capitalize on the growing demand for innovative treatments in neurological and psychiatric disorders. The shift towards personalized medicine and the increasing focus on brain health could position Fallypride as a valuable addition to the therapeutic arsenal.

Conclusion

While Fallypride is still in the early stages of clinical development, its potential in the pharmaceutical market is significant. As the global pharmaceutical market continues to grow, driven by innovations in various therapeutic areas, Fallypride could emerge as a key player if it successfully navigates the clinical trial and regulatory approval process.

Key Takeaways

  • Current Status: Fallypride is in clinical trials, investigating its effects on dopamine release.
  • Mechanism of Action: High-affinity radioligand for D2/3 receptors.
  • Market Projections: Not expected to contribute significantly in the immediate future but holds long-term potential.
  • Competitive Landscape: Evolving rapidly with new modalities and technologies.
  • Challenges and Opportunities: Must navigate regulatory approval and commercialization challenges to capitalize on market potential.

FAQs

Q: What is Fallypride used for? A: Fallypride is being investigated for its effects on striatal and extra-striatal dopamine release, particularly in the context of neurological and psychiatric disorders.

Q: Is Fallypride close to FDA approval? A: As of the latest available data, Fallypride is not close to FDA approval and is still in the clinical trial phase.

Q: How does Fallypride work? A: Fallypride works as a high-affinity radioligand to quantify D2/3 receptors, making it useful in PET investigations.

Q: What are the market projections for Fallypride? A: While Fallypride is not expected to contribute significantly in the immediate future, it holds long-term potential if it demonstrates clinical efficacy and navigates regulatory approval.

Q: What are the challenges Fallypride faces before market launch? A: Fallypride must successfully complete clinical trials, obtain regulatory approval, and develop effective commercialization strategies to ensure patient access and market penetration.

Sources

  1. Norstella, "The practice-changing drugs that will land in 2025," October 15, 2024.
  2. PLOS Computational Biology, "A mathematical model for the role of dopamine-D2 self-regulation in ultradian behavioural rhythms," 2024.
  3. Evaluate, "Evaluate Releases 2030 Forecasts for Global Pharmaceutical Market," July 10, 2024.
  4. DrugBank Online, "Fallypride: Uses, Interactions, Mechanism of Action," May 20, 2019.
  5. Journal of Cerebral Blood Flow & Metabolism, "The applicability of SRTM in [18F]fallypride PET investigations," 2011.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.